[Positive inotropic and lusitropic effect of RP 62719, a new class III antiarrhythmia agent].
Antiarrhythmic drugs, especially the Class I family, exert a negative inotropic effect on the myocardium which is particularly undesirable in patients with depressed left ventricular function. Therefore, research has been directed to the development of new, more specific molecules of the Class III family. The authors studies the mechanical effects of RP 62719 on guinea pig left ventricular papillary muscle. This new molecule is a pure Class III antiarrhythmic, known to lengthen the duration of the cardiac action potential by selectively blocking the potassium current iK1 (inward rectifier K+ current). The mechanical parameters were determined during the phases of contraction and relaxation under isotonic and isometric conditions. At 0.2 and 2 microM concentrations, RP 62719 improved cardiac contraction under both isotonic and isometric conditions with an increase of about 30% of Vmax (p < 0.001), the maximum unloaded shortening velocity delta 1 (p < 0.001), the peak isometric active force normalized per cross-sectional area [AF/S (p < 0.001)]. At these two concentrations, a positive lusitropic effect (improved relaxation) was demonstrated by an increase in negative peak of derivative per mm2-dF/s and maximum lengthening velocity VR max (p < 0.01). At higher concentrations (20 microM), the inotropic and lusitropic effects were less marked with a bell-shaped form of the dose-effect curve. This study indicates that RP 62719 has moderate but significant positive inotropic and lusitropic effects. These actions could provide significant therapeutic advantages especially in patients cardiac failure.
Beregi
J P
JP
Institut national de la santé et de la recherche médicale, Unité 275, LOA-ENSTA, Palaiseau.
Escande
D
D
Coudray
N
N
Chemla
D
D
Mestre
M
M
Péry
N
N
Lecarpentier
Y
Y
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002839:Chromans; D006168:Guinea Pigs; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007537:Isometric Contraction / Q000187:drug effects; D007551:Isotonic Contraction / Q000187:drug effects; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D010210:Papillary Muscles / Q000187:drug effects*; D010880:Piperidines; D015221:Potassium Channels / Q000187:drug effects
D000889:Anti-Arrhythmia Agents; D002839:Chromans; D010880:Piperidines; D015221:Potassium Channels; C063899:terikalant
Action inotrope et lusitrope positive du RP 62719, une nouvelle molécule antiarythmique de classe III.